Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4067-4078

  Tone, Alicia A ^a   Begley, Heather ^a   Sharma, Monika ^b   Murphy, Joan ^a   Rosen, Barry ^a   Brown, Theodore J ^a   Shaw, Patricia A ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ONCOPROTEIN; PROTEIN DAB2; PROTEIN SKIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLICULAR PHASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUTEAL PHASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS CARCINOMA; UTERINE TUBE; CYSTADENOCARCINOMA; EPITHELIUM; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; TUMOR SUPPRESSOR GENE; UTERINE TUBE TUMOR;

ADULT; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; EPITHELIUM; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 48249130869     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4959     Document Type: Article

References (58)

1. Risch H. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98: 1694-705.
2. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-5.
3. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185-92.
4. King MC. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
5. Singer G, Kurman RJ, Chang HW, Cho SK, Shih le M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
6. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-90.
7. Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 2000: 78:278-87.
8. Piek JM, van Diest RJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
9. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6.
10. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
11. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
12. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004; 191:718-32.
13. Lee Y Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
14. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
15. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9.
16. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005;11:6116-26.
17. Riska A, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer 2007;120:1351-4.
18. Pectasides D. Fallopian tube carcinoma: a review. The Oncologist 2006;11:902-12.
19. Pere H, Tapper J, Seppala M, Knuutila S, Butzow R. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res1998;58:4274-6.
20. Nowee M, Snijders A, Rockx D, et al. DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 2007;213:46-55.
21. Dafforn A, Chen P, Deng G, et al. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. BioTechniques 2004;37:3-7.
22. Sultan M, Wigle DA, Cumbaa CA, et al. Binary treestructured vector quantization approach to clustering and visualizing microarray data. Bioinformatics 2002; 18 Suppl 1:S111-9.
23. Brown KR, Jurisica I. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol 2007;8:R95.
24. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
25. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and Beyond. Nat Rev Ca 2004;4:665-76.
26. Boulton SJ. Cellular functions of the BRCA tumoursuppressor proteins. Biochem Soc Trans 2006;34: 633-45.
27. Yoshida K, Miki Y Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95: 866-71.
28. Verhage HG, Bareither ML, Jaffe RC, Akbar M. Cyclic changes in ciliation, secretion and cell height of the oviductal epithelium in women. Am J Anat 1979; 156:505-21.
29. Verhage HG, Fazleabas AT, Mavrogianis PA, et al. Characteristics of an oviductal glycoprotein and its potential role in fertility control. J Reprod Fertil Suppl 1997;51:217-26.
30. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer 2005;12:533-48.
31. Ma Y, Katiyar P, Jones LP, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 2006;20:14-34.
32. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007;17:325-38.
33. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998:90:1774-86.
34. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73.
35. Prat J. Hereditary ovarian cancer. Hum Pathol 2005; 36:861-70.
36. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94: 32-8.
37. McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ. Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp Biol Med (Maywood) 2003; 228:308-14.
38. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
39. Poole AJ, Li Y Kim Y Lin SC, Lee WH, Lee EY Prevention of Brcal - mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70.
40. Shah A. Nandedkar TD, Raghavan VP, Parulekar SV, Natraj U. Characterization and localization of estrogen and progesterone receptors of human fallopian tube. Indian J Exp Biol 1999;37:893-99.
41. Khan MS, Heatley MK. The expression of the proliferation marker Ki-67 and oestrogen and progesterone receptors in the proximal and distal fallopian tube. J Obstet Gynaecol 1999;19:519-21.
42. Rzepka-Gorska I. Tarnowski B, Chudecka-GIaz A, Gorski B, Zielinska D. Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer ResTreat 2006;100:59-63.
43. Reedy MB, Hang T, Gallion H, Arnold S, Smith SA. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis. Gynecol Oncol 2001;81:441-6.
44. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule disabled-2 links the transforming growth factor (i receptors to the Smad pathway. EMBO J 2001;20:2789-801.
45. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 1999;75:72-7.
46. He J. Tegen SB, Krawitz AR, Martin GS, Luo K. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. J Biol Chem 2003;278:30540-7.
47. Karlsson G, Liu YJ, Larsson J, et al. Gene expression profiling demonstrates that TGF-β1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-β signaling. Physiol Genomics 2005;21:396-403.
48. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor β (TGF- β) target genes and distinguishes TGF-β-induced epithelialmesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005;25:8108-25.
49. Ranganathan P, Agrawal A, Bhushan R, et al. Expression profiling of genes regulated by TGF-β: differential regulation in normal and tumour cells. BMC Genomics 2007;8:98-116.
50. Massague J, Gomis RR. The logic of TGFβ signaling. FEBS Lett 2006;580:2811-20.
51. Yarden Rl, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-9.
52. He J, Xu J, Xu XX, Hall RA. Cell cycle-dependent phosphorylation of disabled-2 by cdc2 Oncogene 2003;22:4524-30
53. Vang DH Fazi Z. Smith ER. et al. Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Am J Pathol 2006;169258-67.
54. Santin AD, Zhan F, Bellone S. et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004;112:14-25.
55. Mok SC, Chan WY Wong KK, et al DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998;16:2381-7.
56. Zhang F, Lundin M, Ristimaki A, et al. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-β signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas Cancer Res 2003, 635005-10.
57. Krakowski AR, Laboureau J, Mauviel A. Bissell MJ, Luo K. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-β signaling by sequestration of the Smad proteins. Proc Natl Acad Sci USA2005;102:12437-42.
58. Zhu Q, Krakowski AR, Dunham EE, et al Dual role of SnoN in mammalian tumorigenesis Mol Cell Biol 2007;27:324-39.